Ali Zubair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali Zubair has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Allah Dad
Shiekh Zayed Medical College, Rahim Yar Khan, Pakistan
22 shared publicationsKinza Bakht
Shiekh Zayed Medical College, Rahim Yar Khan, Pakistan
22 shared publicationsMuhammad Arham
Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan
22 shared publicationsHafsa Ahmed
Mclaren Hospital, Oakland, MI, Pontiac, United States
20 shared publicationsHaseeb Tareen
Henry Ford Hospital, Jackson, United States
20 shared publicationsSaif Ali Khan
Northwest Medical Center, Tucson, United States
16 shared publications
Latest Publications
- 24 May 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59  (7) , 1972-1984
Two decades of pulmonary vascular disease and ischemic heart disease mortality in the united states: A longitudinal analysis using CDC WONDER (1999–2020)
Pulmonary vascular disease (PVD) and ischemic heart disease (IHD) are major contributors to cardiovascular mortality in U.S. adults. This retrospective study aims to examine mortality trends and demographic disparities between 1999 and 2020. However, both diseases have been studied individually, but their combined temporal trends remain unexplored. The CDC WONDER database was used to obtain data for adults aged ≥ 45 years. AAMRs per 100,000 population and APC were calculated using Joinpoint regression, stratified by demographic, geographic, and urbanization categories. PVD and IHD together reported a total of 184,780 deaths. The overall AAMR increased from 6.9 to 8.9 per 100,000 between 1999 and 2020. Mortality rates were higher in men (8.8) compared to females (6.0) throughout the study period. Black or African American individuals had the highest AAMR (8.9), demonstrating a current surge in 2018. Similarly, non-metropolitan areas consistently experienced greater AAMR (8.5) than metropolitan areas (6.9), with a steep rise after 2018 (APC = 14.72%). Furthermore, mortality was greatest in the South; however, the Midwest region reported the highest AAMRs (8). Additionally, individuals aged 85 + had the highest CMR (44.6). Lastly, Vermont had the highest AMMRs (13.6) among other states. PVD- and IHD-related mortality depicted a recent steep increase despite an initial decline, with considerable differences across demographic and regional groups. This highlights the importance of a direct call to action by expanding preventive care, spreading awareness, and early diagnosis with management to address these inequities and decrease the growing burden.
- 24 May 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59  (7) , 1972-1984
Two decades of pulmonary vascular disease and ischemic heart disease mortality in the united states: A longitudinal analysis using CDC WONDER (1999–2020)
Pulmonary vascular disease (PVD) and ischemic heart disease (IHD) are major contributors to cardiovascular mortality in U.S. adults. This retrospective study aims to examine mortality trends and demographic disparities between 1999 and 2020. However, both diseases have been studied individually, but their combined temporal trends remain unexplored. The CDC WONDER database was used to obtain data for adults aged ≥ 45 years. AAMRs per 100,000 population and APC were calculated using Joinpoint regression, stratified by demographic, geographic, and urbanization categories. PVD and IHD together reported a total of 184,780 deaths. The overall AAMR increased from 6.9 to 8.9 per 100,000 between 1999 and 2020. Mortality rates were higher in men (8.8) compared to females (6.0) throughout the study period. Black or African American individuals had the highest AAMR (8.9), demonstrating a current surge in 2018. Similarly, non-metropolitan areas consistently experienced greater AAMR (8.5) than metropolitan areas (6.9), with a steep rise after 2018 (APC = 14.72%). Furthermore, mortality was greatest in the South; however, the Midwest region reported the highest AAMRs (8). Additionally, individuals aged 85 + had the highest CMR (44.6). Lastly, Vermont had the highest AMMRs (13.6) among other states. PVD- and IHD-related mortality depicted a recent steep increase despite an initial decline, with considerable differences across demographic and regional groups. This highlights the importance of a direct call to action by expanding preventive care, spreading awareness, and early diagnosis with management to address these inequities and decrease the growing burden.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57  (Suppl_1)
Abstract TP183: Dual burden of Prostate cancer and Stroke in US Men Aged 55 and Older: Insights from Multiple Cause of Death Data
Background: Prostate cancer and stroke remain the leading causes of death among older men in the US. Although examined separately, little has been examined regarding their joint mortality rates. Demographic and geographic differences must be understood for developing targeted prevention interventions and improving outcomes in high-risk populations. Methods: The data regarding mortality was extracted from the CDC Multiple Cause of Death database for U.S. men aged 55 years or older from 2018 to 2023. Information regarding death was identified by using ICD-10 codes when both conditions appeared on the same death certificate. We utilized the Joinpoint Regression Program for estimating age-adjusted mortality rates (AAMRs) per million and annual percent changes (APCs) and stratified them by state, age group, race/ethnicity, and U.S. Census area. Results: The overall mortality rate increased significantly between 2018 and 2023, with the AAMR rising from 61.78 to 80.97 and an average APC (AAPC) of 5.81%. By age group, the overall mortality rate of men aged 55–74 was lower at 17.47 but increased more sharply (AAPC 6.99%) as compared to men aged >75, who had a substantially higher overall mortality rate at 218.10, with slower growth (AAPC 4.24%). By race, the highest mortality rate was observed in non-Hispanic (NH) Black men, with an overall AAMR of 159.97 (AAPC: 7.07%). Although NH Asian men had the lowest mortality rate at 30.98, they experienced the fastest rise (AAPC: 7.70%). NH White men's AAMR was 70.60 (AAPC: 5.73%), whereas Hispanic men's was 53.28 (AAPC: 5.21%). Regionally, the West had the greatest AAMR at 79.92 (AAPC 6.04%), whereas the South had the most rapid increase in mortality (AAPC: 7.50%) and an overall AAMR of 77.17. The Midwest and Northeast had AAMRs of 73.90 (AAPC: 2.90) and 61.08 (AAPC: 5.01), respectively. At the state level, Colorado, Mississippi, Oregon, and Minnesota were among those with the highest mortality rates, whereas Kansas, Massachusetts, Nevada, Illinois, Connecticut, and Arizona had the lowest AAMRs, all below 10 per million. Conclusion: Rising mortality due to combined prostate cancer and stroke burden is being noticed among men in the U.S., and it has the most profound effect within age 75 or above, NH Black men, and southern areas. These results emphasize growing disparities and the need for targeted, data-driven public health strategies.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57  (Suppl_1)
Abstract TP183: Dual burden of Prostate cancer and Stroke in US Men Aged 55 and Older: Insights from Multiple Cause of Death Data
Background: Prostate cancer and stroke remain the leading causes of death among older men in the US. Although examined separately, little has been examined regarding their joint mortality rates. Demographic and geographic differences must be understood for developing targeted prevention interventions and improving outcomes in high-risk populations. Methods: The data regarding mortality was extracted from the CDC Multiple Cause of Death database for U.S. men aged 55 years or older from 2018 to 2023. Information regarding death was identified by using ICD-10 codes when both conditions appeared on the same death certificate. We utilized the Joinpoint Regression Program for estimating age-adjusted mortality rates (AAMRs) per million and annual percent changes (APCs) and stratified them by state, age group, race/ethnicity, and U.S. Census area. Results: The overall mortality rate increased significantly between 2018 and 2023, with the AAMR rising from 61.78 to 80.97 and an average APC (AAPC) of 5.81%. By age group, the overall mortality rate of men aged 55–74 was lower at 17.47 but increased more sharply (AAPC 6.99%) as compared to men aged >75, who had a substantially higher overall mortality rate at 218.10, with slower growth (AAPC 4.24%). By race, the highest mortality rate was observed in non-Hispanic (NH) Black men, with an overall AAMR of 159.97 (AAPC: 7.07%). Although NH Asian men had the lowest mortality rate at 30.98, they experienced the fastest rise (AAPC: 7.70%). NH White men's AAMR was 70.60 (AAPC: 5.73%), whereas Hispanic men's was 53.28 (AAPC: 5.21%). Regionally, the West had the greatest AAMR at 79.92 (AAPC 6.04%), whereas the South had the most rapid increase in mortality (AAPC: 7.50%) and an overall AAMR of 77.17. The Midwest and Northeast had AAMRs of 73.90 (AAPC: 2.90) and 61.08 (AAPC: 5.01), respectively. At the state level, Colorado, Mississippi, Oregon, and Minnesota were among those with the highest mortality rates, whereas Kansas, Massachusetts, Nevada, Illinois, Connecticut, and Arizona had the lowest AAMRs, all below 10 per million. Conclusion: Rising mortality due to combined prostate cancer and stroke burden is being noticed among men in the U.S., and it has the most profound effect within age 75 or above, NH Black men, and southern areas. These results emphasize growing disparities and the need for targeted, data-driven public health strategies.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57  (Suppl_1)
Abstract WP104: National Trends and Disparities in Brain Tumor and Stroke Mortality in U.S. Adults Aged ≥55: 1999–2023
Introduction: Patients with brain tumors face elevated stroke risk, yet national data on their combined mortality burden remain limited. This study examined temporal trends and disparities in mortality when brain tumor and stroke co-occurred as multiple causes of death (MCOD) in U.S. adults aged ≥55 from 1999 to 2023. Methods: Mortality data were extracted from the CDC WONDER database. Deaths with both brain tumor and stroke (ICD-10 codes for neoplasms of the brain and I60–I69) listed as MCOD were identified. Age-adjusted mortality rates (AAMRs) per 1,000,000 population were calculated. Joinpoint regression was used to estimate annual percentage changes (APCs) with 95% confidence intervals (CIs). Analyses were stratified by age, sex, race/ethnicity, census region, and metropolitan versus non-metropolitan residence. Results: From 1999 to 2023, 12,500 deaths were attributed to co-occurring brain tumor and stroke in adults aged ≥55. The overall AAMR increased from 6.26 to 8.61 per 1,000,000, with an APC of +3.88 (95% CI: 2.77–4.99; pConclusion: Mortality associated with co-occurring brain tumor and stroke increased significantly between 1999 and 2023, disproportionately affecting non-Hispanic Whites, rural populations, and residents of the Western U.S. In conclusion, these findings underscore the need for enhanced surveillance and targeted healthcare strategies to reduce disparities among high-risk groups.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57  (Suppl_1)
Abstract WP104: National Trends and Disparities in Brain Tumor and Stroke Mortality in U.S. Adults Aged ≥55: 1999–2023
Introduction: Patients with brain tumors face elevated stroke risk, yet national data on their combined mortality burden remain limited. This study examined temporal trends and disparities in mortality when brain tumor and stroke co-occurred as multiple causes of death (MCOD) in U.S. adults aged ≥55 from 1999 to 2023. Methods: Mortality data were extracted from the CDC WONDER database. Deaths with both brain tumor and stroke (ICD-10 codes for neoplasms of the brain and I60–I69) listed as MCOD were identified. Age-adjusted mortality rates (AAMRs) per 1,000,000 population were calculated. Joinpoint regression was used to estimate annual percentage changes (APCs) with 95% confidence intervals (CIs). Analyses were stratified by age, sex, race/ethnicity, census region, and metropolitan versus non-metropolitan residence. Results: From 1999 to 2023, 12,500 deaths were attributed to co-occurring brain tumor and stroke in adults aged ≥55. The overall AAMR increased from 6.26 to 8.61 per 1,000,000, with an APC of +3.88 (95% CI: 2.77–4.99; pConclusion: Mortality associated with co-occurring brain tumor and stroke increased significantly between 1999 and 2023, disproportionately affecting non-Hispanic Whites, rural populations, and residents of the Western U.S. In conclusion, these findings underscore the need for enhanced surveillance and targeted healthcare strategies to reduce disparities among high-risk groups.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57  (Suppl_1)
Abstract TP004: Mortality Trends in Rheumatoid Arthritis–Associated Stroke in Adults Aged ≥55: An Analysis of the CDC WONDER Database, 1999–2023
Introduction: Rheumatoid arthritis (RA) is associated with increased risks of ischemic and hemorrhagic stroke. This study evaluated national mortality trends due to RA and stroke among U.S. adults aged ≥55 from 1999 to 2023, with emphasis on demographic and geographic disparities. Methods: Mortality data were obtained from the CDC WONDER database. Deaths listing RA (ICD-10: M06) and stroke (ICD-10: I60–I69) as multiple causes of death were analyzed. Age-adjusted mortality rates (AAMRs) per 1,000,000 were calculated. Temporal trends were examined using Joinpoint regression to estimate annual percentage changes (APCs) and average annual percentage changes (AAPCs) with 95% confidence intervals (CIs). Subgroup analyses included sex, race/ethnicity, census region, and urbanization. Results: From 1999–2023, RA-associated stroke accounted for 19,505 deaths. Overall mortality declined from 16.9 to 10.9 per 1,000,000, with an AAPC of –1.7% (95% CI: –2.8 to –0.6; p=0.003). Declines were observed from 1999–2010, stabilization occurred from 2010–2018, and a recent increase emerged after 2018. Men had higher mortality than women, though both groups showed significant declines over time. By race, non-Hispanic Whites had the highest mortality, while Hispanics showed early declines followed by later fluctuations. Regionally, the Midwest and West demonstrated the greatest reductions. By urbanization, medium metropolitan areas saw the largest declines, while non-metropolitan areas showed the least improvement. Conclusion: Mortality from RA-associated stroke has decreased overall since 1999 but has risen again in recent years, with persistent disparities across sex, race, region, and urbanization. In conclusion, these findings emphasize the need for targeted prevention strategies and equitable healthcare access to improve outcomes in high-risk populations.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57  (Suppl_1)
Abstract TP004: Mortality Trends in Rheumatoid Arthritis–Associated Stroke in Adults Aged ≥55: An Analysis of the CDC WONDER Database, 1999–2023
Introduction: Rheumatoid arthritis (RA) is associated with increased risks of ischemic and hemorrhagic stroke. This study evaluated national mortality trends due to RA and stroke among U.S. adults aged ≥55 from 1999 to 2023, with emphasis on demographic and geographic disparities. Methods: Mortality data were obtained from the CDC WONDER database. Deaths listing RA (ICD-10: M06) and stroke (ICD-10: I60–I69) as multiple causes of death were analyzed. Age-adjusted mortality rates (AAMRs) per 1,000,000 were calculated. Temporal trends were examined using Joinpoint regression to estimate annual percentage changes (APCs) and average annual percentage changes (AAPCs) with 95% confidence intervals (CIs). Subgroup analyses included sex, race/ethnicity, census region, and urbanization. Results: From 1999–2023, RA-associated stroke accounted for 19,505 deaths. Overall mortality declined from 16.9 to 10.9 per 1,000,000, with an AAPC of –1.7% (95% CI: –2.8 to –0.6; p=0.003). Declines were observed from 1999–2010, stabilization occurred from 2010–2018, and a recent increase emerged after 2018. Men had higher mortality than women, though both groups showed significant declines over time. By race, non-Hispanic Whites had the highest mortality, while Hispanics showed early declines followed by later fluctuations. Regionally, the Midwest and West demonstrated the greatest reductions. By urbanization, medium metropolitan areas saw the largest declines, while non-metropolitan areas showed the least improvement. Conclusion: Mortality from RA-associated stroke has decreased overall since 1999 but has risen again in recent years, with persistent disparities across sex, race, region, and urbanization. In conclusion, these findings emphasize the need for targeted prevention strategies and equitable healthcare access to improve outcomes in high-risk populations.
- 4 November 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152  (Suppl_3)
Abstract 4365591: The Overlapping Burden: Trends in Cerebrovascular Mortality with Underlying Alzheimer’s Disease in the United States; A nationwide analysis (1999-2023) using CDC Wonder and ARIMA approach
Introduction: Cerebrovascular Disease accounted for more than 5 million deaths in last two decades in the U.S. population. The combined impact of cerebrovascular disease and Alzheimer’s on mortality remains insufficiently demonstrated. This study seeks to evaluate temporal shifts in mortality of adult U.S. population with dual effect of these conditions. Research Question: How have mortality trends among the adult U.S. population evolved from 1999 to 2023 across various demographic and geographic factors? Methods: A retrospective analysis was conducted using CDC WONDER database in adults aged >55 years with cerebrovascular disease (ICD-10: I60-I69) as major cause and Alzheimer’s (G30) as a contributing factor. Age-adjusted Mortality rates per 100,000 population were calculated across different demographic and geographic variables. We assessed Annual percentage changes (APCs) using Bayesian Information Criterion (BIC) approach in Joinpoint regression (JPR) analysis. ARIMA models with Box-Cox transformation were fitted after ADF/KPSS tests. Results: Both conditions reported 72,991 deaths from 1999-2023 in adults aged >55 years with mean annual AAMR of 4.44. The rate is projected to decline to 2.24 (95% CI: -2.14 to 4.07) till 2030 (RMSE: 0.278; Ljung-box p: 0.817). Annual mortality trends displayed consistent decline over the study period with most significant from 2020 to 2023 with APC value of -9.39 (95% CI: -16.71 to -4.82; p=0.00). Females accounted for 70.1% of total deaths, showing an unusual inflection from 2013-20 with APC of 1.86 (95% CI: 0.14-7.47; p=0.03). Male, non-Hispanics and Whites exhibited notable decline in mortality trends with APCs of -10.6 (95% CI: -17.08 to -6.79; p=0.00), -8.89 (95% CI: -16.1 to -4.7; p=0.00) and -9.03 (95% CI: -15.79 to -4.47; p=0.00) from 2020-2023, respectively. CENS R2: Midwest and CENS R3: south observed significant down-trending curve in mortality trends with APC of -5.76(95% CI: -11.86 to -2.16; p=0.008) and -13.79(95% CI: -19.64 to -9.08; p=0.00) from 2020-2023, respectively. Noncore (non-metro: 5.73) and Vermont (7.5) stood highest in terms of AAMR across the whole study period. Among all deaths, 52.32% deaths occurred in nursing homes. Conclusion: Our study revealed consistent decline in mortality trends over the study period, however, significant disparities exist in females, 2013-Urbanization levels and states which suggest the implementation of targeted interventions and sustained healthcare strategies.
- 4 November 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152  (Suppl_3)
Abstract 4365591: The Overlapping Burden: Trends in Cerebrovascular Mortality with Underlying Alzheimer’s Disease in the United States; A nationwide analysis (1999-2023) using CDC Wonder and ARIMA approach
Introduction: Cerebrovascular Disease accounted for more than 5 million deaths in last two decades in the U.S. population. The combined impact of cerebrovascular disease and Alzheimer’s on mortality remains insufficiently demonstrated. This study seeks to evaluate temporal shifts in mortality of adult U.S. population with dual effect of these conditions. Research Question: How have mortality trends among the adult U.S. population evolved from 1999 to 2023 across various demographic and geographic factors? Methods: A retrospective analysis was conducted using CDC WONDER database in adults aged >55 years with cerebrovascular disease (ICD-10: I60-I69) as major cause and Alzheimer’s (G30) as a contributing factor. Age-adjusted Mortality rates per 100,000 population were calculated across different demographic and geographic variables. We assessed Annual percentage changes (APCs) using Bayesian Information Criterion (BIC) approach in Joinpoint regression (JPR) analysis. ARIMA models with Box-Cox transformation were fitted after ADF/KPSS tests. Results: Both conditions reported 72,991 deaths from 1999-2023 in adults aged >55 years with mean annual AAMR of 4.44. The rate is projected to decline to 2.24 (95% CI: -2.14 to 4.07) till 2030 (RMSE: 0.278; Ljung-box p: 0.817). Annual mortality trends displayed consistent decline over the study period with most significant from 2020 to 2023 with APC value of -9.39 (95% CI: -16.71 to -4.82; p=0.00). Females accounted for 70.1% of total deaths, showing an unusual inflection from 2013-20 with APC of 1.86 (95% CI: 0.14-7.47; p=0.03). Male, non-Hispanics and Whites exhibited notable decline in mortality trends with APCs of -10.6 (95% CI: -17.08 to -6.79; p=0.00), -8.89 (95% CI: -16.1 to -4.7; p=0.00) and -9.03 (95% CI: -15.79 to -4.47; p=0.00) from 2020-2023, respectively. CENS R2: Midwest and CENS R3: south observed significant down-trending curve in mortality trends with APC of -5.76(95% CI: -11.86 to -2.16; p=0.008) and -13.79(95% CI: -19.64 to -9.08; p=0.00) from 2020-2023, respectively. Noncore (non-metro: 5.73) and Vermont (7.5) stood highest in terms of AAMR across the whole study period. Among all deaths, 52.32% deaths occurred in nursing homes. Conclusion: Our study revealed consistent decline in mortality trends over the study period, however, significant disparities exist in females, 2013-Urbanization levels and states which suggest the implementation of targeted interventions and sustained healthcare strategies.
- 3 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146  (Supplement) , 8170
Temporal trends and future projections of sepsis mortality in leukemia: A nationwide analysis of demographic and geographic disparities (1999–2030)
Background: Leukemia is a hematologic malignancy characterized by the uncontrolled proliferation of leukocytes, and it is broadly classified as myeloid or lymphoid based on its cellular origin.Patients with leukemia are at increased risk of sepsis due to disease-related and treatment-induced immunosuppression, making sepsis a significant contributor to morbidity and mortality in this population. Understanding trends in sepsis-related mortality among leukemia patients is critical for early recognition, timely intervention, and improved survival outcomes. Methods: We conducted a retrospective, population-based analysis using the CDC WONDER Multiple Cause of Death database to examine sepsis-related mortality among leukemia patients in the United States from 1999 to 2023. Age-adjusted mortality rates (AAMRs) were calculated per million population using U.S. Census data as the denominator. Temporal trends were assessed using Joinpoint regression models to estimate the average annual percent change (AAPC). To forecast future mortality trends from 2024 to 2030, we applied autoregressive integrated moving average (ARIMA) models with Box-Cox transformation, following stationarity tests using the Augmented Dickey-Fuller (ADF) and Kwiatkowski–Phillips–Schmidt–Shin (KPSS) methods. Model performance was validated through residual diagnostics. Subgroup analyses were stratified by sex, race, ethnicity, geographic region, and urbanization level. Results: Between 1999 and 2023, the overall age-adjusted mortality rate (AAMR) in the United States declined from 4.9 to 4.1 per million. Both genders experienced decreases, with AAMR in females falling from 3.4 to 2.7 per million, a 20% reduction, and in males from 7.1 to 5.9 per million, marking a 16.9% decline. By race and ethnicity, White individuals saw a decrease from 4.9 to 4.2 per million, while Black individuals experienced a decline from 5.5 to 4.2 per million, with a notable drop to 3.7 in 2015 (a 32.7% decrease) and 3.9 in 2020 (a 29% decrease). The Asian or Pacific Islander population showed a decline from 3.3 to 2.6 per million. Hispanic or Latino individuals saw their AAMR fall from 3.8 to 3.2, reaching a significant low of 2.5 in 2004. Non-Hispanic individuals also showed a decrease from 4.9 to 4.2 per million. Regionally, the Northeast experienced the greatest improvement, with AAMR dropping from 6.0 to 4.0 per million. The Midwest declined from 4.5 to 3.9, the South from 4.8 to 4.3, and the West showed a modest decrease from 4.3 to 4.1 per million. Urbanization trends revealed increases in AAMRs in non-metro areas (from 4.0 to 4.6 per million) and medium metro areas (from 4.2 to 4.5), while central metro areas experienced a notable decline, from 5.4 to 4.3. Micropolitan regions saw a slight decrease from 4.7 to 4.5, and small metro areas experienced a minor increase from 4.5 to 4.6. Based on ARIMA modeling, the AAMR for sepsis-related mortality in Leukemia is projected to continue rising steadily. Forecasted rates include 4.3 per million in 2024, 2026, 2028, and 2030 (95% CI: 3.91–5.17), suggesting a persistent trend. Conclusions: The Mortality rates due to Leukemia associated sepsis have declined over the past two decades. However, there were significant disparities observed across genders, races, geographic regions, and urbanization levels. Particularly, rural and certain suburban populations have experienced rising or stagnant rates, highlighting areas of concern. Furthermore, projected forecasts exhibited a rising trend till 2030. These findings emphasize the need for targeted interventions in high-risk areas and improved social determinants of health.
- 3 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146  (Supplement) , 8170
Temporal trends and future projections of sepsis mortality in leukemia: A nationwide analysis of demographic and geographic disparities (1999–2030)
Background: Leukemia is a hematologic malignancy characterized by the uncontrolled proliferation of leukocytes, and it is broadly classified as myeloid or lymphoid based on its cellular origin.Patients with leukemia are at increased risk of sepsis due to disease-related and treatment-induced immunosuppression, making sepsis a significant contributor to morbidity and mortality in this population. Understanding trends in sepsis-related mortality among leukemia patients is critical for early recognition, timely intervention, and improved survival outcomes. Methods: We conducted a retrospective, population-based analysis using the CDC WONDER Multiple Cause of Death database to examine sepsis-related mortality among leukemia patients in the United States from 1999 to 2023. Age-adjusted mortality rates (AAMRs) were calculated per million population using U.S. Census data as the denominator. Temporal trends were assessed using Joinpoint regression models to estimate the average annual percent change (AAPC). To forecast future mortality trends from 2024 to 2030, we applied autoregressive integrated moving average (ARIMA) models with Box-Cox transformation, following stationarity tests using the Augmented Dickey-Fuller (ADF) and Kwiatkowski–Phillips–Schmidt–Shin (KPSS) methods. Model performance was validated through residual diagnostics. Subgroup analyses were stratified by sex, race, ethnicity, geographic region, and urbanization level. Results: Between 1999 and 2023, the overall age-adjusted mortality rate (AAMR) in the United States declined from 4.9 to 4.1 per million. Both genders experienced decreases, with AAMR in females falling from 3.4 to 2.7 per million, a 20% reduction, and in males from 7.1 to 5.9 per million, marking a 16.9% decline. By race and ethnicity, White individuals saw a decrease from 4.9 to 4.2 per million, while Black individuals experienced a decline from 5.5 to 4.2 per million, with a notable drop to 3.7 in 2015 (a 32.7% decrease) and 3.9 in 2020 (a 29% decrease). The Asian or Pacific Islander population showed a decline from 3.3 to 2.6 per million. Hispanic or Latino individuals saw their AAMR fall from 3.8 to 3.2, reaching a significant low of 2.5 in 2004. Non-Hispanic individuals also showed a decrease from 4.9 to 4.2 per million. Regionally, the Northeast experienced the greatest improvement, with AAMR dropping from 6.0 to 4.0 per million. The Midwest declined from 4.5 to 3.9, the South from 4.8 to 4.3, and the West showed a modest decrease from 4.3 to 4.1 per million. Urbanization trends revealed increases in AAMRs in non-metro areas (from 4.0 to 4.6 per million) and medium metro areas (from 4.2 to 4.5), while central metro areas experienced a notable decline, from 5.4 to 4.3. Micropolitan regions saw a slight decrease from 4.7 to 4.5, and small metro areas experienced a minor increase from 4.5 to 4.6. Based on ARIMA modeling, the AAMR for sepsis-related mortality in Leukemia is projected to continue rising steadily. Forecasted rates include 4.3 per million in 2024, 2026, 2028, and 2030 (95% CI: 3.91–5.17), suggesting a persistent trend. Conclusions: The Mortality rates due to Leukemia associated sepsis have declined over the past two decades. However, there were significant disparities observed across genders, races, geographic regions, and urbanization levels. Particularly, rural and certain suburban populations have experienced rising or stagnant rates, highlighting areas of concern. Furthermore, projected forecasts exhibited a rising trend till 2030. These findings emphasize the need for targeted interventions in high-risk areas and improved social determinants of health.
- 3 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146  (Supplement) , 6921
Trends in AML vs MDS mortality in the United States older adults from 1999-2023-a CDC wonder database analysis
Introduction: Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) both primarily blood cancers of older age group have an incidence of 4.3 and 4.9 per 100,000 people. AML is the most common acute leukemia in adults, while MDS can lead to AML is 25% of cases with a poor prognosis. Methods: Age-adjusted mortality rates (AAMRs) per 100,000 in adults (65+) were obtained from the CDC WONDER using ICD-10 codes for Acute Myeloid Leukemia (CD92.0) and Myelodysplastic Syndrome (D46). Joinpoint regression estimated Annual Percent Change and Average APC, with significance set at p<0.05 Results: From 1999 to 2023 there were 159994 and 136171 deaths due to to AML and MDS respectively. The overall AAMR was slightly higher for AML than MDS (14.8 vs 12.7). The overall AAMR for AML rose from 12.5 to 14.9 with an Annual Percent Change of 5 by 2001, followed by a fall to 1 between 2011 and 2011, thereafter declining to -0.2 by 2023.AAMR per 100,000 for MDS related deaths rose from 11.7 in 1999 to 13.8 in 2009 with varied APCs declining from 1999 to 2004, before rising again in 2009. From 2009 to 2023 there were fluctuations in APC with -1.9 till 2014 and -2.2 in 2023 with an AAMR of 11.3. For both AML and MDS men had double the AAMR than women, with men having comparable AAMRs (20.2 vs 18.6). NH Whites had the highest AAMRs for AML and MDS related mortality with AAMRs of 15.5 and 13.5 respectively. Regionally, the Midwest had strikingly higher mortality observed in terms of both AML and MDS. Wisconsin had the highest AAMR for AMLwhile South Dakota ranked highest for MDS. Both AML and MDS mortality was comparable across all urbanization groups with Small Metro regions exhibiting higher AAMR in both groups (15.3 vs 13.9). Conclusion: AML related mortality is increasing while MDS related mortality has declined slightly with stable mortality rates. The highest AAMRs for both diseases were observed in NH Whites, men, People in Midwest. Urbanisation did not significantly altered mortality. These findings underscore the need for focused interventions aimed at early cancer screening initiatives to curb both the rising mortality of AML and fixed mortality in MDS, despite newer advancements especially in high risk populations.
- 3 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146  (Supplement) , 6921
Trends in AML vs MDS mortality in the United States older adults from 1999-2023-a CDC wonder database analysis
Introduction: Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) both primarily blood cancers of older age group have an incidence of 4.3 and 4.9 per 100,000 people. AML is the most common acute leukemia in adults, while MDS can lead to AML is 25% of cases with a poor prognosis. Methods: Age-adjusted mortality rates (AAMRs) per 100,000 in adults (65+) were obtained from the CDC WONDER using ICD-10 codes for Acute Myeloid Leukemia (CD92.0) and Myelodysplastic Syndrome (D46). Joinpoint regression estimated Annual Percent Change and Average APC, with significance set at p<0.05 Results: From 1999 to 2023 there were 159994 and 136171 deaths due to to AML and MDS respectively. The overall AAMR was slightly higher for AML than MDS (14.8 vs 12.7). The overall AAMR for AML rose from 12.5 to 14.9 with an Annual Percent Change of 5 by 2001, followed by a fall to 1 between 2011 and 2011, thereafter declining to -0.2 by 2023.AAMR per 100,000 for MDS related deaths rose from 11.7 in 1999 to 13.8 in 2009 with varied APCs declining from 1999 to 2004, before rising again in 2009. From 2009 to 2023 there were fluctuations in APC with -1.9 till 2014 and -2.2 in 2023 with an AAMR of 11.3. For both AML and MDS men had double the AAMR than women, with men having comparable AAMRs (20.2 vs 18.6). NH Whites had the highest AAMRs for AML and MDS related mortality with AAMRs of 15.5 and 13.5 respectively. Regionally, the Midwest had strikingly higher mortality observed in terms of both AML and MDS. Wisconsin had the highest AAMR for AMLwhile South Dakota ranked highest for MDS. Both AML and MDS mortality was comparable across all urbanization groups with Small Metro regions exhibiting higher AAMR in both groups (15.3 vs 13.9). Conclusion: AML related mortality is increasing while MDS related mortality has declined slightly with stable mortality rates. The highest AAMRs for both diseases were observed in NH Whites, men, People in Midwest. Urbanisation did not significantly altered mortality. These findings underscore the need for focused interventions aimed at early cancer screening initiatives to curb both the rising mortality of AML and fixed mortality in MDS, despite newer advancements especially in high risk populations.
- 3 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146  (Supplement) , 7395
Blood and filters: The intersection of myelodysplastic syndrome and renal failure in u.S. mortality trends (1999–2023)
Introduction: Myelodysplastic syndromes (MDS) are clonal bone marrow disorders with a major worldwide and U.S. health burden. Myelodysplastic syndromes (MDS) primarily affect older adults, with the average age at diagnosis being around 71 years. The global incidence is notably higher in men, with a World Standardized Incidence Rate (WSIR) of 3.4 per 100,000 person-years, compared to 1.6 in women. Renal failure (RF) and worsening patient outcomes can be due to immune dysregulation in Myelodysplastic syndromes. This study examines MDS with renal failure-related mortality trends among US adults from 1999 to 2023, considering demographic and geographic disparities. Methodology: The CDC WONDER multiple cause of death database was used to identify the U.S. population aged ≥65 years with myelodysplastic syndrome (ICD-10: D46) and renal failure (ICD-10: N17–N19) listed on death certificates from 1999 to 2023. Age-adjusted mortality rates (AAMRs) per 100,000 were extracted and annual percent change (APC) with 95 % confidence intervals (CIs) were calculated using Monte Carlo permutation test in JoinPoint regression analysis. Results were stratified by year, sex, race/ethnicity, urbanization, and Census regions. Results: Between 1999 and 2023; 18,698 deaths were attributed to MDS and RF as a multiple cause in patients aged 65 and above. There was an increase in annual AAMR with an overall AAPC of 0.99% (95% CI: 1.89 to 3.95; p = 0.5060) which is statistically non-significant. A statistically significant incline was observed specifically between 1999 and 2012 (APC: 4.12%; 95% CI: 2.84–5.40; p < 0.0001). This was followed by a non-significant decline from 2012 to 2015 and a modest, also non-significant, increase thereafter. Regionally, the Midwest recorded the highest AAMR (1.19) and steepest rise (AAPC: 1.80%; 95% CI: 0.23–3.41). The South (AAMR: 1.07; AAPC: 1.37%; 95% CI: –0.66 to 3.39) and West (AAMR: 0.97; AAPC: 0.47%; 95% CI: –2.75 to 1.26) followed. The Northeast showed the lowest AAMR (0.81) and slowest growth (AAPC: 0.42%; 95% CI: –0.43 to 1.28). States with the highest AAMR were South Dakota (3.5), Minnesota (3.3), and Vermont (3). Regarding sex, males had a higher AAMR (1.46) and AAPC (1.25%; 95% CI: –0.90 to 3.44; p = 0.2576) compared to females (AAMR: 0.91; AAPC: 0.77%; 95% CI: –0.89 to 2.47; p = 0.3662). Neither sex-specific trend was statistically significant. Among ethnic groups, Hispanic individuals showed a statistically significant decline in mortality (AAPC: –1.55%; 95% CI: –2.77 to –0.31; p = 0.0171). Non-Hispanic Whites had a stable trend (AAPC: –0.41%; 95% CI: –1.50 to 0.67; p = 0.4362). Non-Hispanic Blacks showed a non-significant decline (AAPC: –1.25%; 95% CI: –5.12 to 2.77; p = 0.5356), while other racial groups had a non-significant upward trend (AAPC: 1.25%; 95% CI: –1.05 to 3.80; p = 0.2891). Across urbanization levels, AAPCs ranged from –0.10% (95% CI: –0.83 to 0.64) in completely rural areas to 1.38% (95% CI: –1.04 to 3.87) in highly urbanized zones. No statistically significant trends were observed across any urbanization level (all p > 0.26).Conclusion: Myelodysplastic syndromes with renal failure mortality in US adults aged ≥65 showed a significant rise from 1999 to 2012, followed by non-significant changes probably due to improvement in treatment strategies. The Midwest recorded the highest mortality rates and steepest increases, and males had higher rates than females. Hispanic individuals experienced a significant decline, while other ethnic groups and urbanization levels showed non-significant trends. These certain disparities stress upon the need for targeted intervention and a multidisciplinary approach.
- 3 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146  (Supplement) , 7395
Blood and filters: The intersection of myelodysplastic syndrome and renal failure in u.S. mortality trends (1999–2023)
Introduction: Myelodysplastic syndromes (MDS) are clonal bone marrow disorders with a major worldwide and U.S. health burden. Myelodysplastic syndromes (MDS) primarily affect older adults, with the average age at diagnosis being around 71 years. The global incidence is notably higher in men, with a World Standardized Incidence Rate (WSIR) of 3.4 per 100,000 person-years, compared to 1.6 in women. Renal failure (RF) and worsening patient outcomes can be due to immune dysregulation in Myelodysplastic syndromes. This study examines MDS with renal failure-related mortality trends among US adults from 1999 to 2023, considering demographic and geographic disparities. Methodology: The CDC WONDER multiple cause of death database was used to identify the U.S. population aged ≥65 years with myelodysplastic syndrome (ICD-10: D46) and renal failure (ICD-10: N17–N19) listed on death certificates from 1999 to 2023. Age-adjusted mortality rates (AAMRs) per 100,000 were extracted and annual percent change (APC) with 95 % confidence intervals (CIs) were calculated using Monte Carlo permutation test in JoinPoint regression analysis. Results were stratified by year, sex, race/ethnicity, urbanization, and Census regions. Results: Between 1999 and 2023; 18,698 deaths were attributed to MDS and RF as a multiple cause in patients aged 65 and above. There was an increase in annual AAMR with an overall AAPC of 0.99% (95% CI: 1.89 to 3.95; p = 0.5060) which is statistically non-significant. A statistically significant incline was observed specifically between 1999 and 2012 (APC: 4.12%; 95% CI: 2.84–5.40; p < 0.0001). This was followed by a non-significant decline from 2012 to 2015 and a modest, also non-significant, increase thereafter. Regionally, the Midwest recorded the highest AAMR (1.19) and steepest rise (AAPC: 1.80%; 95% CI: 0.23–3.41). The South (AAMR: 1.07; AAPC: 1.37%; 95% CI: –0.66 to 3.39) and West (AAMR: 0.97; AAPC: 0.47%; 95% CI: –2.75 to 1.26) followed. The Northeast showed the lowest AAMR (0.81) and slowest growth (AAPC: 0.42%; 95% CI: –0.43 to 1.28). States with the highest AAMR were South Dakota (3.5), Minnesota (3.3), and Vermont (3). Regarding sex, males had a higher AAMR (1.46) and AAPC (1.25%; 95% CI: –0.90 to 3.44; p = 0.2576) compared to females (AAMR: 0.91; AAPC: 0.77%; 95% CI: –0.89 to 2.47; p = 0.3662). Neither sex-specific trend was statistically significant. Among ethnic groups, Hispanic individuals showed a statistically significant decline in mortality (AAPC: –1.55%; 95% CI: –2.77 to –0.31; p = 0.0171). Non-Hispanic Whites had a stable trend (AAPC: –0.41%; 95% CI: –1.50 to 0.67; p = 0.4362). Non-Hispanic Blacks showed a non-significant decline (AAPC: –1.25%; 95% CI: –5.12 to 2.77; p = 0.5356), while other racial groups had a non-significant upward trend (AAPC: 1.25%; 95% CI: –1.05 to 3.80; p = 0.2891). Across urbanization levels, AAPCs ranged from –0.10% (95% CI: –0.83 to 0.64) in completely rural areas to 1.38% (95% CI: –1.04 to 3.87) in highly urbanized zones. No statistically significant trends were observed across any urbanization level (all p > 0.26).Conclusion: Myelodysplastic syndromes with renal failure mortality in US adults aged ≥65 showed a significant rise from 1999 to 2012, followed by non-significant changes probably due to improvement in treatment strategies. The Midwest recorded the highest mortality rates and steepest increases, and males had higher rates than females. Hispanic individuals experienced a significant decline, while other ethnic groups and urbanization levels showed non-significant trends. These certain disparities stress upon the need for targeted intervention and a multidisciplinary approach.
- 3 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146  (Supplement) , 6715
Rising sepsis-related mortality in aplastic anemia: A u.S. population-based analysis of temporal trends, disparities, and forecasts through 2030
Background: Patients with aplastic anemia (AA) are at increased risk of sepsis-related mortality due to underlying immunosuppression and bone marrow failure. Despite advances in treatment, sepsis remains a leading cause of death in this population. This study analyzes trends in sepsis-related mortality among AA patients in the U.S. from 1999 to 2023, with a focus on disparities by sex, race/ethnicity, geographic region, and urbanization status, and forecasts mortality trends through 2030. Methods: Age-adjusted mortality rates (AAMR) were calculated using national mortality data from the CDC WONDER database. Records were filtered to include deaths with ICD-10 code D61 (Aplastic Anemia) and ICD-10 code A41 (Sepsis) listed among the multiple causes of death. Temporal trends were identified using Joinpoint regression analysis, and future mortality rates were projected using ARIMA modeling. Stratified analyses were performed by sex, census region, state, race/ethnicity, and level of urbanization. Statistical significance was determined at a threshold of p < 0.05. Results: From 1999 to 2023, a total of 20,436 sepsis-related deaths occurred among AA patients. The AAMR initially declined from 19.1 (95% CI: 17.6–20.6) in 1999 to 16.3 (95% CI: 15.0–17.6) in 2001 but rose to 23.0 (95% CI: 21.8–24.3) by 2023. Males consistently exhibited higher mortality rates than females, with rates of 27.9 and 19.3, respectively, in 2023. Marked geographic disparities were observed, with the South recording the highest AAMR (24.9 in 2023), and states such as Kentucky (27.1) and Texas (26.1) exceeding the national average. Racial and ethnic analyses revealed persistently elevated mortality among Black individuals (25.8 in 2023), while Asian/Pacific Islanders experienced early declines followed by later increases. Urban-rural trends varied, with micropolitan areas peaking at an AMR of 23.8 (95% CI: 19.5–28.1) in 2020. Forecasts for 2021–2030 project stable but uncertain mortality trends, with an estimated AAMR of 19.5 (95% CI: 11.38–27.22) by 2030. Conclusion: Sepsis-related mortality among AA patients has increased significantly since the early 2000s, with pronounced disparities by sex, race, and geographic regions. The sustained rise, particularly among males and in Southern states highlights critical gaps in prevention and clinical management. Projections indicate no near-term improvement, emphasizing the urgent need for targeted interventions in high-risk populations.
- 3 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146  (Supplement) , 6715
Rising sepsis-related mortality in aplastic anemia: A u.S. population-based analysis of temporal trends, disparities, and forecasts through 2030
Background: Patients with aplastic anemia (AA) are at increased risk of sepsis-related mortality due to underlying immunosuppression and bone marrow failure. Despite advances in treatment, sepsis remains a leading cause of death in this population. This study analyzes trends in sepsis-related mortality among AA patients in the U.S. from 1999 to 2023, with a focus on disparities by sex, race/ethnicity, geographic region, and urbanization status, and forecasts mortality trends through 2030. Methods: Age-adjusted mortality rates (AAMR) were calculated using national mortality data from the CDC WONDER database. Records were filtered to include deaths with ICD-10 code D61 (Aplastic Anemia) and ICD-10 code A41 (Sepsis) listed among the multiple causes of death. Temporal trends were identified using Joinpoint regression analysis, and future mortality rates were projected using ARIMA modeling. Stratified analyses were performed by sex, census region, state, race/ethnicity, and level of urbanization. Statistical significance was determined at a threshold of p < 0.05. Results: From 1999 to 2023, a total of 20,436 sepsis-related deaths occurred among AA patients. The AAMR initially declined from 19.1 (95% CI: 17.6–20.6) in 1999 to 16.3 (95% CI: 15.0–17.6) in 2001 but rose to 23.0 (95% CI: 21.8–24.3) by 2023. Males consistently exhibited higher mortality rates than females, with rates of 27.9 and 19.3, respectively, in 2023. Marked geographic disparities were observed, with the South recording the highest AAMR (24.9 in 2023), and states such as Kentucky (27.1) and Texas (26.1) exceeding the national average. Racial and ethnic analyses revealed persistently elevated mortality among Black individuals (25.8 in 2023), while Asian/Pacific Islanders experienced early declines followed by later increases. Urban-rural trends varied, with micropolitan areas peaking at an AMR of 23.8 (95% CI: 19.5–28.1) in 2020. Forecasts for 2021–2030 project stable but uncertain mortality trends, with an estimated AAMR of 19.5 (95% CI: 11.38–27.22) by 2030. Conclusion: Sepsis-related mortality among AA patients has increased significantly since the early 2000s, with pronounced disparities by sex, race, and geographic regions. The sustained rise, particularly among males and in Southern states highlights critical gaps in prevention and clinical management. Projections indicate no near-term improvement, emphasizing the urgent need for targeted interventions in high-risk populations.
- 3 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146  (Supplement) , 7193
Comparative mortality trends of hematological malignancies with and without sepsis among older adults in the United States: A population-based study (1999–2023)
Introduction: Leukemias, lymphomas, and multiple myeloma are among the hematologic malignancies that pose a significant health burden both internationally and domestically in the United States. These cancers have a high rate of death and morbidity due to their aggressive clinical course and the intensity of the treatments they necessitate. A patient's risk of infection is increased by immunosuppression caused by the cancer and its treatment. Sepsis is one of the most common causes of complications, extended hospital stays, and fatalities among these. This study examines mortality trends between 1999 and 2023 for adults in the United States who had hematologic malignancies and those who had hematologic malignancies with sepsis. Methodology: Data were retrieved from the CDC WONDER database for the years 1999 to 2023, including individuals aged ≥65 years. Firstly we evaluated mortality trends among people diagnosed with hematologic malignancies(C81-C96) and hematologic malignancies with sepsis(A41) individually. Then, we conducted a head-to-head analysis to determine differences between both groups. We assessed age-adjusted mortality rates (AAMRs) per 100,000 population as stratified by age, sex, race, Hispanic origin, U.S. Census regions, and 2013 urbanization categories. Joinpoint regression (JPR) was used to estimate Annual Percent Changes (APCs) and corresponding 95% confidence intervals (CIs), with statistical significance determined via Monte Carlo permutation test (p < 0.05). Results: Between 1999 and 2023, there were 1,133,287 deaths due to hematological malignancies and 92,409 deaths where hematological malignancies co-occurred with sepsis. The overall age-adjusted mortality rate (AAMR) was higher for hematological malignancies (124.2) than for those with sepsis (10.3), though both declined significantly (AAPC: -1.05; 95% CI: -1.36 to -0.75, p < 0.000001 and AAPC: -0.45; 95% CI: -0.61 to -0.29, p < 0.000006, respectively). The highest AAMRs were recorded in 2000 (142.66 and 11.0).Males had nearly double the AAMR compared to females in both groups (166 vs 95.21 and 14.03 vs 7.3). Among males with hematological malignancies, mortality declined modestly from 1999 to 2018 (APC: -1.26, p < 0.000001), with a similar trend in females (APC: -1.68, p < 0.000001). Non-Hispanic White individuals had a higher AAMR (128.14) with a declining trend (AAPC: -0.94; 95% CI: -1.26 to -0.61, p < 0.000001). Non-Hispanic Black individuals with sepsis had the highest AAMR (12.22) and also showed a decline (AAPC: -0.96; 95% CI: -1.25 to -0.67, p < 0.000001). Hispanic/Latino individuals showed a steady decline (AAPC: -0.68, p < 0.000001), while non-Hispanics showed rising mortality from 2018 to 2021 (APC: 2.92, p < 0.007) with a higher AAMR (126.59).Regionally, the Midwest had the highest AAMR for hematological malignancies (136.15), while the Northeast led in the sepsis group (10.8). By urbanization, micropolitan areas had the highest AAMR for hematological malignancies (130.9), with a declining trend (AAPC: -0.73, p < 0.000001). In contrast, large central metro areas had the highest AAMR for the sepsis cohort (10.62) with a sharp decline (AAPC: -1.09). Statistically significant declines were also noted in large fringe (AAPC: -1.18), medium (APC: -0.14), and small metro areas (APC: -0.04). This urban–rural reversal is unique to the sepsis cohort and highlights growing geographic disparities.States with the highest AAMRs for hematological malignancies included Minnesota (146.13), Iowa (142.66), and Nebraska (142.12); for hematological malignancies with sepsis, the highest rates were in the District of Columbia (13.61), New Jersey (13.62), and Rhode Island (13.02). Conclusion:The study revealed a three-phase mortality pattern for hematologic malignancies, with a pivotal increase post-2018, especially for males and non-Hispanic individuals. Conversely, sepsis-associated mortality consistently declined across most demographics, including all racial categories. However, rural areas saw increases in sepsis-related mortality, highlighting an urban-rural healthcare gap. This disparity underscores the complex, divergent trends between these overlapping conditions.
- 3 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146  (Supplement) , 7193
Comparative mortality trends of hematological malignancies with and without sepsis among older adults in the United States: A population-based study (1999–2023)
Introduction: Leukemias, lymphomas, and multiple myeloma are among the hematologic malignancies that pose a significant health burden both internationally and domestically in the United States. These cancers have a high rate of death and morbidity due to their aggressive clinical course and the intensity of the treatments they necessitate. A patient's risk of infection is increased by immunosuppression caused by the cancer and its treatment. Sepsis is one of the most common causes of complications, extended hospital stays, and fatalities among these. This study examines mortality trends between 1999 and 2023 for adults in the United States who had hematologic malignancies and those who had hematologic malignancies with sepsis. Methodology: Data were retrieved from the CDC WONDER database for the years 1999 to 2023, including individuals aged ≥65 years. Firstly we evaluated mortality trends among people diagnosed with hematologic malignancies(C81-C96) and hematologic malignancies with sepsis(A41) individually. Then, we conducted a head-to-head analysis to determine differences between both groups. We assessed age-adjusted mortality rates (AAMRs) per 100,000 population as stratified by age, sex, race, Hispanic origin, U.S. Census regions, and 2013 urbanization categories. Joinpoint regression (JPR) was used to estimate Annual Percent Changes (APCs) and corresponding 95% confidence intervals (CIs), with statistical significance determined via Monte Carlo permutation test (p < 0.05). Results: Between 1999 and 2023, there were 1,133,287 deaths due to hematological malignancies and 92,409 deaths where hematological malignancies co-occurred with sepsis. The overall age-adjusted mortality rate (AAMR) was higher for hematological malignancies (124.2) than for those with sepsis (10.3), though both declined significantly (AAPC: -1.05; 95% CI: -1.36 to -0.75, p < 0.000001 and AAPC: -0.45; 95% CI: -0.61 to -0.29, p < 0.000006, respectively). The highest AAMRs were recorded in 2000 (142.66 and 11.0).Males had nearly double the AAMR compared to females in both groups (166 vs 95.21 and 14.03 vs 7.3). Among males with hematological malignancies, mortality declined modestly from 1999 to 2018 (APC: -1.26, p < 0.000001), with a similar trend in females (APC: -1.68, p < 0.000001). Non-Hispanic White individuals had a higher AAMR (128.14) with a declining trend (AAPC: -0.94; 95% CI: -1.26 to -0.61, p < 0.000001). Non-Hispanic Black individuals with sepsis had the highest AAMR (12.22) and also showed a decline (AAPC: -0.96; 95% CI: -1.25 to -0.67, p < 0.000001). Hispanic/Latino individuals showed a steady decline (AAPC: -0.68, p < 0.000001), while non-Hispanics showed rising mortality from 2018 to 2021 (APC: 2.92, p < 0.007) with a higher AAMR (126.59).Regionally, the Midwest had the highest AAMR for hematological malignancies (136.15), while the Northeast led in the sepsis group (10.8). By urbanization, micropolitan areas had the highest AAMR for hematological malignancies (130.9), with a declining trend (AAPC: -0.73, p < 0.000001). In contrast, large central metro areas had the highest AAMR for the sepsis cohort (10.62) with a sharp decline (AAPC: -1.09). Statistically significant declines were also noted in large fringe (AAPC: -1.18), medium (APC: -0.14), and small metro areas (APC: -0.04). This urban–rural reversal is unique to the sepsis cohort and highlights growing geographic disparities.States with the highest AAMRs for hematological malignancies included Minnesota (146.13), Iowa (142.66), and Nebraska (142.12); for hematological malignancies with sepsis, the highest rates were in the District of Columbia (13.61), New Jersey (13.62), and Rhode Island (13.02). Conclusion:The study revealed a three-phase mortality pattern for hematologic malignancies, with a pivotal increase post-2018, especially for males and non-Hispanic individuals. Conversely, sepsis-associated mortality consistently declined across most demographics, including all racial categories. However, rural areas saw increases in sepsis-related mortality, highlighting an urban-rural healthcare gap. This disparity underscores the complex, divergent trends between these overlapping conditions.